INVESTORS

Operations

Cohera is an early-stage company developing a novel suite of surgical adhesives for the medical industry. The Company is focused on completing pre-clinical testing for it's lead product, TissuGlu®, in preparation for entry into human clinical trials. The chemistry underlying our product formulation is straightforward and highly scalable, and Cohera has already established relationships with key raw material providers. A GMP (Good Manufacturing Practices) manufacturing facility has been identified and has completed pilot scale synthesis. In addition to the financing below, Cohera has secured an additional $2 Million in non-dilutive grant support through the SBIR program for the development of its products.

Financing

In August 2006, we completed a Series A financing in which we raised $6.8M from private investors. The proceeds from this transaction are anticipated to support the growth og the company through Phase I clinical trials of its lead product TissuGlu®.

In May, 2008, we completed an insider round of financing in which we raised over $7.6 million. The proceeds are being used to support TissuGlu® development through pilot clinical trials as well as preclinical development of the company's product line.  

In October 2008, we completed a Series B financing for a total of $16.1 million. The proceeds will be used to support clinical trials for TissuGlu® and initial sales and marketing efforts.